Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 2Surgical Wound Infection 1Inflammatory Bowel Diseases 1Diverticulitis 1

Interventions

Cyclophosphamide 2040Radiotherapy 1854Cisplatin 1820Carboplatin 1530Gemcitabine 1432Paclitaxel 1289Bevacizumab 1267Docetaxel 1200pembrolizumab 1196Oxaliplatin 1157Capecitabine 1140Fluorouracil 1059Dexamethasone 971Rituximab 918Nivolumab 908Magnetic Resonance Spectroscopy 858Etoposide 839Doxorubicin 823Drug Therapy 789Radiosurgery 774Irinotecan 774Cytarabine 736fludarabine 714Leucovorin 674Lenalidomide 608fludarabine phosphate 564Temozolomide 552Filgrastim 540Radiation 539Cetuximab 535

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × Benchmarking × Clear all
NCT04729322 2025-12-23

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
15 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT03042091 2018-08-22

Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery

Thomas Jefferson University

Phase EARLY_PHASE1 Unknown
224 enrolled
Gastrointestinal

Diverticulitis, Surgical Wound Infection, Colorectal Neoplasms, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡